Yahoo Web Search

Sign In

Search results

  1. en.wikipedia.org › wiki › Tetsuya_NaitoTetsuya Naito - Wikipedia

    2 days ago · Tetsuya Naito (内藤哲也, Naitō Tetsuya, born June 22, 1982) is a Japanese professional wrestler. He is signed to New Japan Pro-Wrestling (NJPW), where he is the current IWGP World Heavyweight Champion in his record-tying second reign and is the leader of the Los Ingobernables de Japón stable.

  2. www.fiercebiotech.com › biotech › fierce-biotech-layoffFierce Biotech Layoff Tracker 2024

    4 days ago · March 13 - Takeda: After an unsuccessful attempt to sell an Austrian manufacturing and development site, Takeda is calling it quits on much of the operations at the facility.

    • Gabrielle Masson

  3. www.asiaone.com › business › ascentage-pharma-received-us100Ascentage Pharma Received US$100 Million Option Payment from...

    3 days ago · On June 14, 2024, Ascentage Pharma and Takeda entered into an Exclusive Option Agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for olverembatinib.

  4. stockanalysis.com › stocks › takTakeda Pharmaceutical Company Limited (TAK) - Stock Analysis

    3 days ago · Get a real-time Takeda Pharmaceutical Company Limited (TAK) stock price quote with breaking news, financials, statistics, charts and more.

    • 40.39B
    • 28.16B
    • 951.57M
    • 3.14B
    • Tetsuya Takeda1
    • Tetsuya Takeda2
    • Tetsuya Takeda3
    • Tetsuya Takeda4
    • Tetsuya Takeda5

  5. stockanalysis.com › stocks › takTakeda Pharmaceutical Company Limited (TAK) Company Profile &...

    3 days ago · Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

  6. www.biospace.com › article › releasesAscentage Pharma Received US$100 Million Option Payment from...

    3 days ago · Ascentage Pharma announced that on July 2, 2024, in relation to the Exclusive Option Agreement with Takeda for the third-generation BCR-ABL inhibitor olverembatinib, Ascentage Pharma has received the US$100 million option payment called for by the Exclusive Option Agreement.

  7. simplywall.st › tse-4502 › takeda-pharmaceutical-sharesTakeda Pharmaceutical TSE:4502 Stock Report - Simply Wall St

    3 days ago · Research Takeda Pharmaceutical's (TSE:4502) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.